Patent · US Active

5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta

US8993583B2 · kind B2 · utility

22Cited by

53References

13Claims

0Family size

Assignee

ICOS CORPORATION · US

Inventors

Kerry W. Fowler · Seattle, US
Danwen Huang · New York, US
Edward A. Kesicki · Bothell, US
Hua Chee Ooi · Kirkland, US
Amy Oliver · Bothell, US
Fuqiang Ruan · Bellevue, US
Jennifer Treiberg · Redmond, US
Kamal D. Puri · Seattle, US

Key dates

Filing date	Oct 8, 2013
Grant date	Mar 31, 2015
Priority date	—
Expiry date	Oct 8, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed. Exemplary compounds disclosed in this application are shown below:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.